The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.
By Sushree Mohanty
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
By Annika Kim Constantino
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine
By Robb M. Stewart
Multicomponent Vaccine for COVID-19, Influenza Shows Promise in Phase 3 Trial
Pharmalittle: We're reading about a Moderna flu vaccine, a J&J loss over 340B rebate plans, and more
By Ed Silverman
mRNA Flu Vaccine Meets Primary End Point Among Older Adults
Full Coverage of this storyModerna Stock Is Climbing. It Has Been a Tumultuous Few Days for Pharma.
By Mackenzie Tatananni
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
By Youri Benadjaoud & Mary Kekatos
RFK Jr.'s anti-vax moves mean Moderna has much to lose
By jonathan saltzman
How Moderna Went From Pandemic Hero to Vaccine Victim
By Peter Loftus & Jared S. Hopkins
A road map for startups, from Moderna’s co-founder
By Betsy Vereckey
Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19 | npj Vaccines
By Adewunmi Akingbola, Kolade James Adegoke & Joel Chuku
Moderna chief brand officer Kate Cronin exits pharma giant
By Diana Bradley
Trump team weighs pulling funds for Moderna Bird Flu Vaccine
By Riley Griffin, Ike Swetlitz & Madison Muller
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
By Youri Benadjaoud & Meredith Deliso
Moderna: Fair Value Lowered on ‘Hostile’ FDA Environment
By Karen Andersen
Bancel says Moderna's RSV strategy was 'too optimistic'
By Elizabeth Eaton
Moderna shares jump on insider stock purchases
By Angela Harmantas & Emily Jarvie
S&P 500 Gains and Losses Today: Moderna Soars on Bird Flu Vaccine Potential
By Michael Bromberg
StockWatch: Moderna Seeks to Reassure Investors on RFK Jr.
By Alex Philippidis
Moderna earnings beat forecasts, but analysts question whether sales spike will last
By Ned Pagliarulo
Moderna CEO Bancel steps down as sales chief, Bloomberg News reports
By Bhanvi Satija & Krishna Chandra Eluri
Vaccine stocks hit by Robert Kennedy Jr nomination
By Ian Johnston & Oliver Barnes
ESMO 2024: Moderna's mRNA solid tumour vaccine shows early promise
By Abigail Beaney
StockWatch: Moderna’s $1.1B R&D Cut, Profitability Delay Jolt Investors
By Alex Philippidis
Moderna reports encouraging results on its mpox vaccine, as outbreaks in Africa spread
By Helen Branswell
Moderna, trailing rivals, checks its RSV shot expectations
By Delilah Alvarado
Moderna stock falls 20% as it slashes guidance on low EU sales, tough U.S. vaccine market
By Annika Kim Constantino
Should Merck Buy Out Moderna on Keytruda–Cancer Vaccine Partnership?
By Jef Akst & Tyler Patchen
New Covid vaccine: Independent pharmacies report delays as Pfizer and Moderna doses roll out
By Berkeley Lovelace Jr.
Top 6 Moderna Government Contracts Award
By Paula Marasigan
Moderna Leans into Oncology with CytomX Deal Worth up to $1.2B
By Tristan Cesar Manalac
Buying hype doesn’t work – the case of Moderna
By Chris Beauchamp
Moderna COVID vaccine deal worth $2b blasted
By Liam Mannix & Paul Sakkal
Moderna co-founder on taking risks to make a difference - ABC listen
By Rafael Epstein